In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Contineum Therapeutics Inc (NASDAQ: CTNM) was $10.76 for the day, up 0.47% from the previous closing price of $10.71. In other words, the price has increased by $0.47 from its previous closing price. On the day, 0.12 million shares were traded. CTNM stock price reached its highest trading level at $10.99 during the session, while it also had its lowest trading level at $10.5.
Ratios:
Our analysis of CTNM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 29.07 and its Current Ratio is at 29.07. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on November 13, 2025, initiated with a Outperform rating and assigned the stock a target price of $22.
On September 25, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $20.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTNM now has a Market Capitalization of 314003840 and an Enterprise Value of 137089824.
Stock Price History:
The Beta on a monthly basis for CTNM is 1.27, which has changed by -0.28169012 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, CTNM has reached a high of $15.40, while it has fallen to a 52-week low of $3.35. The 50-Day Moving Average of the stock is -4.66%, while the 200-Day Moving Average is calculated to be 44.91%.
Shares Statistics:
CTNM traded an average of 185.36K shares per day over the past three months and 243460 shares per day over the past ten days. A total of 22.77M shares are outstanding, with a floating share count of 18.74M. Insiders hold about 36.50% of the company’s shares, while institutions hold 47.54% stake in the company. Shares short for CTNM as of 1763078400 were 1190737 with a Short Ratio of 6.42, compared to 1760486400 on 1148688. Therefore, it implies a Short% of Shares Outstanding of 1190737 and a Short% of Float of 5.6900002.
Earnings Estimates
A detailed examination of Contineum Therapeutics Inc (CTNM) is currently in progress, with 7.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.49 and low estimates of -$0.76.
Analysts are recommending an EPS of between -$1.19 and -$2.28 for the fiscal current year, implying an average EPS of -$2.07. EPS for the following year is -$2.31, with 7.0 analysts recommending between -$1.9 and -$2.74.
